- ICH GCP
- US Clinical Trials Registry
- Klinisk forsøg NCT03013972
A Longitudinal Study of Cancer-related Fatigue Among Colorectal Cancer Patients During Adjuvant Chemotherapy
Worldwide, nearly 1.25 million patients are diagnosed with and more than 600,000 patients die from colorectal cancer each year. The third leading cause of death is colorectal cancer in Taiwan 2012. The current treatments for colorectal cancer including surgery, chemotherapy and/or radiotherapy are prescribed to improve survival and lower the risk of recurrence. However, disease and treatment-related toxicities in cancer patients may result in fatigue and interfered quality of life (QoL). Previous studies have reported that cancer-related fatigue (CRF) is the most common symptom experienced by patients at all stage of diseases, it can occur during treatment, in advanced disease and in disease-free survivors; the prevalence of fatigue is reported to be between 59-96% in patients undergoing chemotherapy, 65-100% in patients receiving radiation therapy, and 30% in long term survivors. Also, CRF has been reported as the most frequent and distressing toxicity of colon and rectal chemotherapy. The National Comprehensive Cancer Network (NCCN) has published guidelines for the definition of CRF as ''a persistent subjective sense of physical, emotional, and/or cognitive tiredness or exhaustion related to cancer or cancer treatment that is not proportional to recent activity and that significantly interferes with usual functioning." Besides, CRF could dynamically change with the interactions among disease progression, treatment regimen, tumor site, nutrition, infection or other factors. Therefore, to minimize the impact of CRF on cancer patients, more in-depth researches on CRF are needed.
The aim of this longitudinal study is to examine the dynamic changes, correlated factors and QoL of CRF among colorectal cancer patients during adjuvant chemotherapy. Furthermore, the results will supply physicians with more understanding about CRF, and help them to enhance the quality on cancer care to being perfected in the future.
Studieoversigt
Status
Betingelser
Detaljeret beskrivelse
Undersøgelsestype
Tilmelding (Forventet)
Kontakter og lokationer
Studiesteder
-
-
-
Taipei, Taiwan, 104
- Rekruttering
- MacKay Memorial Hospital
-
Kontakt:
- Hsi-Hsien Hsu, M.D., Ph.D.
- Telefonnummer: 886-975-835784
- E-mail: hsu5936@ms3.hinet.net
-
Ledende efterforsker:
- Hsi-Hsien Hsu, M.D., Ph.D.
-
Underforsker:
- Ming-Jen Chen, M.D., Ph.D.
-
Underforsker:
- Chien-Kuo Liu, M.D.
-
-
Deltagelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Prøveudtagningsmetode
Studiebefolkning
Beskrivelse
Inclusion Criteria:
- Patients who signed the informed consent form
- Aged 20 years and older
- Patients who have been given a diagnosis of stage II-IV colorectal cancer
- Scheduled to receive adjuvant chemotherapy
- Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2
- Able to communicate verbally and completely fill out the questionnaires
Exclusion Criteria:
- Female patients are pregnant or breast-feeding
- Patients have enrolled or have not yet completed other investigational drug trials within 30 days before screening
- Patients who have been given a diagnosis of cognitive impairment are unable to complete the questionnaires
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
Kohorter og interventioner
Gruppe / kohorte |
|---|
|
Colorectal cancer patients
Colorectal cancer patients during adjuvant chemotherapy
|
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Tidsramme |
|---|---|
|
Cancer-related fatigue evaluation by brief fatigue inventory-Taiwanese form(BFI-T)
Tidsramme: Change from baseline cancer-related fatigue at 12 chemotherapy cycles(24 weeks).
|
Change from baseline cancer-related fatigue at 12 chemotherapy cycles(24 weeks).
|
Sekundære resultatmål
Resultatmål |
Tidsramme |
|---|---|
|
Quality of life assessments by functional assessment of cancer therapy-general 7 (FACT-G7)
Tidsramme: Change from baseline quality of life at 12 chemotherapy cycles(24 weeks).
|
Change from baseline quality of life at 12 chemotherapy cycles(24 weeks).
|
Samarbejdspartnere og efterforskere
Sponsor
Efterforskere
- Ledende efterforsker: Hsi-Hsien Hsu, M.D., Ph.D., MacKay Memorial Hospital
Datoer for undersøgelser
Studer store datoer
Studiestart
Primær færdiggørelse (Forventet)
Studieafslutning (Forventet)
Datoer for studieregistrering
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først opslået (Skøn)
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Skøn)
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Nøgleord
Yderligere relevante MeSH-vilkår
Andre undersøgelses-id-numre
- CRF-CRC01
Plan for individuelle deltagerdata (IPD)
Planlægger du at dele individuelle deltagerdata (IPD)?
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .
Kliniske forsøg med ColoRektal Cancer
-
University of ArkansasRekrutteringColorectal cancer og inflammatorisk tarmsygdomForenede Stater
-
University Health Network, TorontoAstraZenecaAktiv, ikke rekrutterendeAdenocarcinom i bugspytkirtlen | Leiomyosarkom | Mismatch Reparation Proficient Colorectal CancerCanada
-
Stingray TherapeuticsRekrutteringRefractory Metastatic Microsatellite Stabil Colorectal Cancer (MSS-CRC)Forenede Stater
-
IRCCS Azienda Ospedaliero-Universitaria di BolognaIkke rekrutterer endnuKolorektal kirurgi | Robotkirurgi | Colorectal cancer og inflammatorisk tarmsygdom
-
Tianjin Medical University Cancer Institute and...RekrutteringMSI-H Advanced Colorectal CancerKina
-
Bristol-Myers SquibbAfsluttetMikrosatellit stabil kolorektal cancer | Mismatch Reparation Proficient Colorectal Cancer | Mikrosatellit ustabil kolorektal cancer | Mismatch Reparation Manglende tyktarmskræftForenede Stater, Australien, Belgien, Canada, Irland, Italien, Spanien, Frankrig
-
Syndax PharmaceuticalsMerck Sharp & Dohme LLCAfsluttetMelanom | Ikke-småcellet lungekræft | Mismatch Reparation-Proficient Colorectal CancerForenede Stater